Ellevest Inc’s CytomX Therapeutics CTMX Stock Holding History

Ellevest Inc’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-201	Closed	–	–	1654
2022 Q2	$0	Buy	201 +188	+1,446%	+$360	﹤0.01%	1441
2022 Q1	$0	Buy	+13	New	+$50	﹤0.01%	1454

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Ellevest Inc's CTMX Position: Q3 2022 in Review

Ellevest Inc sold out of CytomX Therapeutics (CTMX) in Q3 2022, closing a stake of 201 shares.

Ellevest Inc first reported a position in CTMX in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 84 funds tracked by Wall St. Rank hold CTMX as of Q3 2022.

Ellevest Inc reported no remaining CytomX Therapeutics position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 201 CytomX Therapeutics shares in Q3 2022.
Ellevest Inc first reported a position in CytomX Therapeutics in Q1 2022 and held it in 2 quarters.
Ellevest Inc's CytomX Therapeutics position peaked at $0 in Q2 2022.
84 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.